|Bid||0.140200 x 1800|
|Ask||0.143000 x 3000|
|Day's Range||0.1331 - 0.1486|
|52 Week Range||0.0800 - 3.3500|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.25|
HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.
WALTHAM, Mass., Nov. 29, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
While a competitor stumbles, Cambridge-based cell therapy biotech Vericel Corp. recently saw its share hit a new high after the company announced that its knee cartilage regeneration product could help far more patients than originally thought.
On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...
WALTHAM, Mass., Nov. 08, 2018 -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to.
WALTHAM, Mass., Nov. 01, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.
WALTHAM, Mass., Oct. 25, 2018 -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and.
NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX) is a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. On September 5, 2018 HSGX announced that its Phase III clinical trial did not meet one of its primary endpoints, a measurement of pain and knee function after a year compared to microfracture surgery.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.
Histogenics Corp (NASDAQ: HSGX) shares were losing more than half their market value Wednesday following the release of top-line data from the Phase 3 trial of Neocart, its pipeline candidate to treat knee cartilage damage. Histogenics, a developer of restorative cell therapies, said Neocart did not meet the primary endpoint of statistically significant improvement in pain and function in a dual threshold responder analysis a year after treatment relative to microfracture. In the modified Intent to Treat population, which excludes patients randomized but not treated with Neocart, 74.2 percent showed clinically meaningful improvement in pain and function compared to 62 percent of microfracture patients at one year, which was deemed to be statistically insignificant.
The Waltham, Massachusetts-based company said it had a loss of 13 cents per share. Losses, adjusted for non-recurring gains, were 25 cents per share. The results missed Wall Street expectations. The average ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Histogenics Corp. (NASDAQ: HSGX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. ...